Show simple item record

dc.contributor.authorBratlie, Kaitlin M
dc.contributor.authorYork, Roger L.
dc.contributor.authorInvernale, Michael A.
dc.contributor.authorLanger, Robert S
dc.contributor.authorAnderson, Daniel Griffith
dc.date.accessioned2017-05-31T15:24:25Z
dc.date.available2017-05-31T15:24:25Z
dc.date.issued2012-05
dc.date.submitted2012-02
dc.identifier.issn2192-2640
dc.identifier.urihttp://hdl.handle.net/1721.1/109461
dc.description.abstractThis review is focused on the materials and methods used to fabricate closed-loop systems for type 1 diabetes therapy. Herein, we give a brief overview of current methods used for patient care and discuss two types of possible treatments and the materials used for these therapies–(i) artificial pancreases, comprised of insulin producing cells embedded in a polymeric biomaterial, and (ii) totally synthetic pancreases formulated by integrating continuous glucose monitors with controlled insulin release through degradable polymers and glucose-responsive polymer systems. Both the artificial and the completely synthetic pancreas have two major design requirements: the device must be both biocompatible and be permeable to small molecules and proteins, such as insulin. Several polymers and fabrication methods of artificial pancreases are discussed: microencapsulation, conformal coatings, and planar sheets. We also review the two components of a completely synthetic pancreas. Several types of glucose sensing systems (including materials used for electrochemical, optical, and chemical sensing platforms) are discussed, in addition to various polymer-based release systems (including ethylene-vinyl acetate, polyanhydrides, and phenylboronic acid containing hydrogels).en_US
dc.description.sponsorshipJuvenile Diabetes Research Foundation International (17-2007-1063)en_US
dc.description.sponsorshipLeona M. and Harry B. Helmsley Charitable Trust (09PG-T1D027)en_US
dc.description.sponsorshipUnited States. National Institutes of Health (F32 EB011580-01)en_US
dc.language.isoen_US
dc.publisherWiley Blackwellen_US
dc.relation.isversionofhttp://dx.doi.org/10.1002/adhm.201200037en_US
dc.rightsCreative Commons Attribution-Noncommercial-Share Alikeen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/en_US
dc.sourcePMCen_US
dc.titleMaterials for Diabetes Therapeuticsen_US
dc.typeArticleen_US
dc.identifier.citationBratlie, Kaitlin M.; York, Roger L.; Invernale, Michael A.; Langer, Robert and Anderson, Daniel G. “Materials for Diabetes Therapeutics.” Advanced Healthcare Materials 1, no. 3 (April 2012): 267–284 © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheimen_US
dc.contributor.departmentHarvard University--MIT Division of Health Sciences and Technologyen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Chemical Engineeringen_US
dc.contributor.departmentKoch Institute for Integrative Cancer Research at MITen_US
dc.contributor.mitauthorBratlie, Kaitlin M
dc.contributor.mitauthorYork, Roger L.
dc.contributor.mitauthorInvernale, Michael A.
dc.contributor.mitauthorLanger, Robert S
dc.contributor.mitauthorAnderson, Daniel Griffith
dc.relation.journalAdvanced Healthcare Materialsen_US
dc.eprint.versionAuthor's final manuscripten_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dspace.orderedauthorsBratlie, Kaitlin M.; York, Roger L.; Invernale, Michael A.; Langer, Robert; Anderson, Daniel G.en_US
dspace.embargo.termsNen_US
dc.identifier.orcidhttps://orcid.org/0000-0003-4255-0492
dc.identifier.orcidhttps://orcid.org/0000-0001-5629-4798
mit.licenseOPEN_ACCESS_POLICYen_US
mit.metadata.statusComplete


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record